Uscript Author ManuscriptReference1. Doran MF, Crowson CS, Pond GR, et al.
Uscript Author ManuscriptReference1. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. GDNF Protein medchemexpress arthritis Rheumatism. 2002; 46(9):2294sirtuininhibitor00. [PubMed: 12355476] two. Capell HA. Disease modifying antirheumatic drugs: longterm security concerns. J Rheumatol Suppl. 2001; 62:10sirtuininhibitor. Epub 2001/06/21. [PubMed: 11409152] 3. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the threat of hospitalization for infection in patients with autoimmune diseases. JAMA : the journal of your American Medical Association. 2011; 306(21):2331sirtuininhibitor. Epub 2011/11/08. 4. Curtis JR, Patkar N, Xie A, et al. Threat of really serious bacterial infections amongst rheumatoid arthritis individuals exposed to tumor necrosis issue alpha antagonists. Arthritis Rheum. 2007; 56(4):1125sirtuininhibitor3. [PubMed: 17393394] five. Curtis JR, Xie F, Chen L, et al. The comparative threat of significant infections amongst rheumatoid arthritis individuals beginning or switching biological agents. Ann Rheum Dis. 2011; 70(8):1401sirtuininhibitor. Epub 2011/05/19. [PubMed: 21586439] six. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent dangers of bacterial infection amongst patients with rheumatoid arthritis who were exposed to tumor necrosis element alpha antagonists. Arthritis Rheum. 2007; 56(12):4226sirtuininhibitor. [PubMed: 18050253] 7. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific threat of tuberculosis in individuals with rheumatoid arthritis treated with anti-TNF therapy: Final results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2009 Epub 2009/10/27. eight. Dixon WG, Symmons DP, Lunt M, et al. Critical infection following anti-tumor necrosis factor alpha therapy in individuals with rheumatoid arthritis: lessons from interpreting data from observational research. Arthritis Rheum. 2007; 56(9):2896sirtuininhibitor04. Epub 2007/09/01. [PubMed: 17763441] 9. Johnston SS, Turpcu A, Shi N, et al. Threat of infections in rheumatoid arthritis sufferers switching from anti-TNF IFN-beta Protein Formulation agents to rituximab, abatacept, or an additional anti-TNF agent, a retrospective administrative claims evaluation. Seminars in arthritis and rheumatism. 2013 Epub 2013/03/05. ten. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis aspect alpha therapy along with the danger of significant bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007; 56(6):1754sirtuininhibitor4. [PubMed: 17530704] 11. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52(11):3403sirtuininhibitor2. [PubMed: 16255017] 12. Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse effect of anti-tumor necrosis factor-alpha biologics in treatment of rheumatoid arthritis: 5 years follow-up. International journal of rheumatic ailments. 2012; 15(3):330sirtuininhibitor. Epub 2012/06/20. [PubMed: 22709496] 13. Keyser FD. Selection of Biologic Therapy for Sufferers with Rheumatoid Arthritis: The Infection Point of view. Current rheumatology reviews. 2011; 7(1):77sirtuininhibitor7. Epub 2011/11/15. [PubMed: 22081766] 14. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Seminars in arthritis and rheumatism. 2010; 39(5):327sirtuininhibitor6. Epub 2009/01/02. [PubMed: 19117595] 15. Hyrich KL, Lunt M, Watson KD, et al. Outcomes soon after switching from one particular anti-tumor necrosis element alpha agent to a.